Medpace Holdings, Inc. (MEDP)
$149.6
Rating:
Recommendation:
Buy
| Symbol | MEDP |
|---|---|
| Price | $149.6 |
| Beta | 1.532 |
| Volume Avg. | 0.34M |
| Market Cap | 4.797B |
| Shares () | - |
| 52 Week Range | 126.945-231.0 |
| 1y Target Est | - |
| DCF Unlevered | MEDP DCF -> | |
|---|---|---|
| DCF Levered | MEDP LDCF -> | |
| ROE | 24.17% | Buy |
| ROA | 14.87% | Buy |
| Operating Margin | - | |
| Debt / Equity | 122.20% | Buy |
| P/E | 28.60 | Strong Buy |
| P/B | 8.63 | Strong Buy |
Latest MEDP news
About
Download (Excel)Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.